Labroots

Dementia Drug Linked to Higher Stroke Risk

Risperidone, an antipsychotic drug commonly used for severe agitation or aggressive behavior, increases stroke risk in patients with dementia. | Neuroscience ...

Common drug linked to 'hidden stroke' risk in dementia patients, study finds

A major study involving over 160,000 dementia patients has found that risperidone, a commonly prescribed antipsychotic drug, is associated with higher stroke risk across all dementia patient groups ...
Science Daily

165,000 dementia patients reveal hidden stroke risk from common drug

A massive UK study of more than 165,000 dementia patients has uncovered troubling new evidence about risperidone, a commonly ...
Hosted on MSN

This widely used dementia drug may raise stroke risk in all patients, study finds

A major UK study tracking more than 165,000 people living with dementia has found that risperidone raises the risk of stroke across all patients, calling into question the long-held belief that the ...
Monthly Prescribing Reference

Risperidone Orally-disintegrating Tabs

Risperidone 0.5mg, 1mg, 2mg, 3mg, 4mg; contains phenylalanine. Initially 2–3mg once daily; may adjust at intervals of at least 24hrs by 1mg/day. Usual range: 1–6mg/day; max 6mg/day. Elderly, ...
Irish Star on MSN

Alarming study finds common dementia drug may be linked to 'hidden strokes'

Risperidone is the only drug of its kind licensed for dementia, but a new study has revealed that it poses a high risk of stroke for all dementia patients—contrary to the previously held belief that t ...
Business Wire

UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...
Business Wire

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that four studies across its ...
Nasdaq

Teva Pharmaceuticals Reports Positive Real-World Outcomes for UZEDY® (risperidone) in Schizophrenia Treatment Compared to Second-Generation Oral Antipsychotics

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...
Nasdaq

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...
New Atlas

Weekly schizophrenia pill produces promising results in final-stage trial

A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.